How Should Multiple Device Models Be Grouped in a Singapore Medical Device Registration Submission?

Multiple models can generally be grouped into a single Singapore registration submission when they share the same risk classification, intended purpose, technology platform, materials of construction, manufacturing site and sterilisation status, and when one set of technical documentation, type-test reports, risk management files, clinical evidence and labelling covers every model in the group. Where models differ in risk class, intended use, sterility, energy source, software or IVD characteristics, they normally need to be separated into different applications or supported by additional model-specific evidence. Before filing, the company should confirm the target country, product risk class, applicable regulatory route and existing documentation base, then assess technical documentation, quality management system evidence, labelling and instructions for use, the local representative, clinical evidence and post-market obligations. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, evidence coverage or authorisation arrangements do not extend the project timeline.

Publication date: 11 July 2026, 10:50 | Updated: 11 July 2026, 10:50

This article addresses the questions companies most often need to resolve first in international medical device registration, documentation preparation, regulatory pathways and post-market maintenance.

Executive Summary

On the question of how to group multiple models in a Singapore medical device registration, companies should first confirm the target country, product risk class, applicable regulatory route and existing documentation base, and then assess technical documentation, quality management system evidence, labelling and instructions for use, the local representative, clinical evidence and post-market maintenance requirements. AIMEILI recommends a documentation gap assessment before formal submission to avoid extended timelines caused by unclear classification, evidence or authorisation arrangements.

For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and only then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Singapore registration typically affects technical documentation, the authorised representative, importer cooperation, labelling language, quality management system evidence and subsequent change maintenance at the same time. If the project is driven only by a list of documents to be submitted, deficiencies and rework are likely to arise in model coverage, evidence chain consistency, labelling claims and certificate control. AIMEILI recommends positioning this question within a GHWP member state and multi-country market access strategy, using one reusable core technical file to support localisation in different markets, rather than rebuilding documentation on an ad hoc basis for each country.

Applicable Scenarios and Core Questions

Companies searching for guidance on grouping multiple models in a Singapore registration are usually not looking for a conceptual explanation. They need to judge whether their existing documentation can support a Singapore submission, whether a local agent or authorised representative is required, why timelines are being extended, and which issues could affect the launch plan. Behind this question there are typically several interrelated elements: product classification, registration route, evidence chain, labelling localisation and post-market maintenance responsibility.

If a company intends to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America at the same time, answering the process for a single country is not sufficient. A more valuable approach is to first build reusable versions of the core technical file, quality management system evidence, performance verification, clinical evidence and labelling, and then localise them in line with each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the intended use, mechanism of action, clinical setting, mode of body contact, duration of use, sterility, whether the device is powered, and whether it contains software or has IVD characteristics. Only then should the risk class and submission route be determined. Once the route is wrong, the subsequent translation, notarisation, authorisation, testing and supplementary submissions will all move in the wrong direction.

For a Singapore project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market incidents, who triggers changes, and who maintains the documentation for renewal. If these points are left vague in a commercial contract, market control can easily be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or other applicable quality management system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labelling and instructions for use, authorisation documents, existing registration certificates, manufacturer's declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. IFU claims, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support one another. Regulators focus on whether the device is safe, effective and traceable for its intended use, not on how many documents have been uploaded.

Common Pitfalls

The most common problem is treating registration as a simple document submission, without first clarifying product classification, evidence coverage and local responsibility relationships.

• Translating NMPA documentation directly and submitting it without restructuring the evidence according to the Singapore route.
• Too many model variants, but insufficient coverage in test reports, clinical evidence or labelling.
• Selecting a local agent purely on sales cooperation criteria, without defining regulatory responsibility, certificate control or post-market maintenance obligations.
• Inconsistency between labels, IFUs, promotional material and registration documentation, leading to deficiency letters or post-market compliance risk.
• Failure to plan multi-country documentation reuse in advance, resulting in duplicated preparation for each country and inflated cost and timelines.

Company Preparation Checklist

Before starting the project, companies should use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare ISO 13485 certificates, test reports, risk management files, clinical evaluation and English IFUs.
• Confirm the responsibilities, fees, certificate control and exit mechanism of the local agent or authorised representative.
• Build a country-specific gap assessment table identifying what needs additional testing, translation, notarisation or supplementary declarations.

AIMEILI Perspective

AIMEILI recommends that companies treat Singapore registration not as a one-off document submission but as an overseas market access programme. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it to national requirements is usually faster, more stable and more conducive to later changes and renewals than filling documentation gaps country by country.

From a project management perspective, three things should be controlled in advance: first, product classification and route determination; second, consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of the local partner. If these three items are unclear, repeated rounds of deficiency responses, agent communication and post-market maintenance are likely even when the documentation appears extensive.

Frequently Asked Follow-up Questions

Can domestic (NMPA) documentation be used directly for Singapore registration?

Domestic documentation can serve as a starting point, but it usually cannot be submitted as it stands. Companies need to restructure the documentation, language, labelling, authorisation documents and evidence chain in line with local regulatory requirements.

When is the best time to start the gap assessment?

Immediately after the target markets and product list have been confirmed. The earlier the gap assessment is completed, the easier it is to schedule additional testing, translation, label adjustment and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent typically participates in registration communication, changes, renewals and the handling of post-market incidents. Unclear responsibilities and rights affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing this type of registration project, companies should maintain a project ledger that manages the product list, model specifications, registration route, documentation owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This allows documentation gaps to be identified promptly and helps management judge whether the project will affect the launch plan.

For companies with existing registrations in several countries, an evidence reuse matrix should also be established, clarifying which documents can serve as core evidence and which must be reissued or supplemented for specific national requirements. Labelling and IFUs, clinical evaluation, risk management, performance verification and quality system certificates in particular must be kept version-consistent.

• Confirm the target markets and product list.
• Complete risk classification and route determination.
• Establish a documentation gap assessment table.
• Clarify the local agent and certificate control.
• Track translation, notarisation, testing and deficiency response status.
• Assign post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a review perspective, quality system documentation is not an isolated certificate. Regulators typically examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards and technical documentation are consistent with one another. If the scope of the ISO 13485 certificate does not match the products being registered, or if the manufacturing address, model specifications or IFU version differ from the test reports, clarifying information may be requested even when a large volume of documentation has been prepared.

Before submission, companies should build an evidence consistency checklist that maps product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labelling and IFU version, and quality system certificates item by item. This appears basic, but it noticeably reduces the probability of deficiency letters, particularly for projects registering simultaneously in several GHWP member states or across multiple product families.

Localisation and Representative Responsibilities

Singapore registration projects usually involve arrangements for a local agent, authorised representative, importer or registration holder. Companies must confirm in advance whether the local partner is responsible only for submitting documentation, or also for regulatory communication, certificate maintenance, post-market incident reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labelling, IFUs and authorisation documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorised representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localisation is converting reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of documents.

Post-Market Maintenance and Long-Term Planning

Registration is not the end of compliance work. Companies also need to maintain certificate validity, change records, distributor authorisations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance; when a manufacturing site change, model extension, IFU update or agent replacement occurs, the certificate and market sales can easily become disconnected.

AIMEILI recommends managing this issue as part of an annual international registration plan: first define target market priorities, then build a reusable documentation package and country gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value lies not only in improving registration efficiency for a single country, but in enabling the company to build a repeatable overseas compliance capability and reduce the cost of rebuilding documentation from scratch each time it enters a new market.

Further Reading

• Previous: What should be prepared before renewing a Singapore medical device registration?
• Next: What are the requirements for risk management documentation in Singapore medical device registration?
• Recommended: What are the requirements for risk management documentation in Philippine medical device registration?
• Recommended: How should performance verification documentation be prepared for Philippine medical device registration?
• Recommended: What should be done when quality system evidence is inconsistent in Philippine medical device registration?
• Recommended: How should registration documentation be prepared for Singapore medical device registration?
• Recommended: How is product classification determined for Singapore medical device registration?
• Recommended: How should the technical file be organised for Singapore medical device registration?

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team.

Source principles: priority is given to official regulatory authorities, international organisations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting references.

Scope of application: this article supports preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice. Specific projects should follow the latest requirements of the target country's regulatory authority and the product's documentation base.